Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. Summary This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: The subject must have already received tremelimumab in another protocol Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator. Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures Exclusion Criteria: None
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Research Site Los Angeles California, 90024, United States
Research Site Tampa Florida, 33612, United States
Research Site Ann Arbor Michigan, 48109, United States
Research Site New York New York, 10016, United States
Research Site Houston Texas, 77030, United States
Research Site Newecastle Upon Tyne , NE7 7, United Kingdom
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up